(BWAY) Brainsway - Overview
Stock: Deep, Transcranial, Magnetic, Stimulation, Platform
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 50.7% |
| Relative Tail Risk | -8.67% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.57 |
| Alpha | 90.21 |
| Character TTM | |
|---|---|
| Beta | 0.967 |
| Beta Downside | 1.203 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.33% |
| CAGR/Max DD | 3.40 |
Description: BWAY Brainsway December 31, 2025
BrainsWay Ltd. (NASDAQ:BWAY) is a Jerusalem-based medical-technology firm that commercializes a Deep Transcranial Magnetic Stimulation (dTMS) platform for non-invasive neurostimulation across a broad spectrum of mental-health and neurological indications, including major depressive disorder, obsessive-compulsive disorder, PTSD, and chronic pain.
Founded in 2003, the company markets its dTMS devices to psychiatrists, hospitals, and specialty clinics in the United States, East Asia, and other international markets, positioning itself within the GICS “Health Care Equipment” sub-industry.
Key performance indicators as of the most recent quarter show a 22 % year-over-year increase in device shipments and a 15 % rise in recurring service revenue, reflecting growing adoption of neurostimulation as a reimbursable therapy in the U.S. Medicare and private-payer landscape.
Sector drivers that underpin BrainsWay’s growth include expanding insurance coverage for TMS procedures, an aging global population increasing demand for dementia-related therapies, and heightened investor focus on non-pharmacologic treatments for treatment-resistant psychiatric disorders.
For a deeper dive into the company’s valuation dynamics and how they compare to peers, a quick look at ValueRay’s analytical toolkit can help you surface the most material risk-adjusted opportunities.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 6.25m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 7.95 > 1.0 |
| NWC/Revenue: 116.0% < 20% (prev 115.6%; Δ 0.42% < -1%) |
| CFO/TA 0.20 > 3% & CFO 22.2m > Net Income 6.25m |
| Net Debt (-63.7m) to EBITDA (8.79m): -7.25 < 3 |
| Current Ratio: 3.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.0m) vs 12m ago 13.94% < -2% |
| Gross Margin: 74.92% > 18% (prev 0.75%; Δ 7417 % > 0.5%) |
| Asset Turnover: 53.03% > 50% (prev 53.58%; Δ -0.55% > 0%) |
| Interest Coverage Ratio: 2.33 > 6 (EBITDA TTM 8.79m / Interest Expense TTM 3.00m) |
Altman Z'' -1.08
| A: 0.50 (Total Current Assets 82.9m - Total Current Liabilities 26.0m) / Total Assets 113.1m |
| B: -0.83 (Retained Earnings -93.7m / Total Assets 113.1m) |
| C: 0.08 (EBIT TTM 6.97m / Avg Total Assets 92.6m) |
| D: -2.09 (Book Value of Equity -89.8m / Total Liabilities 43.0m) |
| Altman-Z'' Score: -1.08 = CCC |
Beneish M -0.77
| DSRI: 1.15 (Receivables 5.13m/3.52m, Revenue 49.1m/38.6m) |
| GMI: 1.00 (GM 74.92% / 74.57%) |
| AQI: 4.53 (AQ_t 0.14 / AQ_t-1 0.03) |
| SGI: 1.27 (Revenue 49.1m / 38.6m) |
| TATA: -0.14 (NI 6.25m - CFO 22.2m) / TA 113.1m) |
| Beneish M-Score: -0.77 (Cap -4..+1) = D |
What is the price of BWAY shares?
Over the past week, the price has changed by -6.84%, over one month by +2.01%, over three months by +39.70% and over the past year by +104.70%.
Is BWAY a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BWAY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.3 | 20.9% |
| Analysts Target Price | 26.3 | 20.9% |
| ValueRay Target Price | 26.9 | 23.6% |
BWAY Fundamental Data Overview February 03, 2026
P/E Forward = 61.7284
P/S = 9.4689
P/B = 6.5592
Revenue TTM = 49.1m USD
EBIT TTM = 6.97m USD
EBITDA TTM = 8.79m USD
Long Term Debt = 6.75m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.04m USD (from shortTermDebt, last quarter)
Debt = 6.75m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -63.7m USD (from netDebt column, last quarter)
Enterprise Value = 401.2m USD (464.9m + Debt 6.75m - CCE 70.5m)
Interest Coverage Ratio = 2.33 (Ebit TTM 6.97m / Interest Expense TTM 3.00m)
EV/FCF = 21.87x (Enterprise Value 401.2m / FCF TTM 18.3m)
FCF Yield = 4.57% (FCF TTM 18.3m / Enterprise Value 401.2m)
FCF Margin = 37.37% (FCF TTM 18.3m / Revenue TTM 49.1m)
Net Margin = 12.73% (Net Income TTM 6.25m / Revenue TTM 49.1m)
Gross Margin = 74.92% ((Revenue TTM 49.1m - Cost of Revenue TTM 12.3m) / Revenue TTM)
Gross Margin QoQ = 75.19% (prev 75.20%)
Tobins Q-Ratio = 3.55 (Enterprise Value 401.2m / Total Assets 113.1m)
Interest Expense / Debt = 8.46% (Interest Expense 571.0k / Debt 6.75m)
Taxrate = 13.38% (242.0k / 1.81m)
NOPAT = 6.04m (EBIT 6.97m * (1 - 13.38%))
Current Ratio = 3.19 (Total Current Assets 82.9m / Total Current Liabilities 26.0m)
Debt / Equity = 0.10 (Debt 6.75m / totalStockholderEquity, last quarter 70.1m)
Debt / EBITDA = -7.25 (Net Debt -63.7m / EBITDA 8.79m)
Debt / FCF = -3.47 (Net Debt -63.7m / FCF TTM 18.3m)
Total Stockholder Equity = 66.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.75% (Net Income 6.25m / Total Assets 113.1m)
RoE = 9.46% (Net Income TTM 6.25m / Total Stockholder Equity 66.1m)
RoCE = 9.57% (EBIT 6.97m / Capital Employed (Equity 66.1m + L.T.Debt 6.75m))
RoIC = 9.14% (NOPAT 6.04m / Invested Capital 66.1m)
WACC = 9.45% (E(464.9m)/V(471.6m) * Re(9.48%) + D(6.75m)/V(471.6m) * Rd(8.46%) * (1-Tc(0.13)))
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 6.93%
[DCF Debug] Terminal Value 76.70% ; FCFF base≈13.4m ; Y1≈16.5m ; Y5≈28.1m
Fair Price DCF = 21.99 (EV 367.0m - Net Debt -63.7m = Equity 430.7m / Shares 19.6m; r=9.45% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 80.11 | EPS CAGR: 14.33% | SUE: -2.47 | # QB: 0
Revenue Correlation: 78.38 | Revenue CAGR: 13.26% | SUE: 2.19 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.04 | Chg30d=-0.002 | Revisions Net=+2 | Analysts=3
EPS next Year (2026-12-31): EPS=0.27 | Chg30d=-0.017 | Revisions Net=-1 | Growth EPS=+57.7% | Growth Revenue=+25.4%